EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
EpiVario has raised $275K in total funding. The most recent round was Grant. The last funding was announced in October 2024.
EpiVario's investors include National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism.
EpiVario is headquartered in Philadelphia, United States.
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
EpiVario is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EpiVario — Funding & Investors." VCBacked, October 1, 2024, https://www.vcbacked.co/company/epivario. Accessed August 14, 2026.
VCBacked. (2024). EpiVario — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/epivario
{{cite web |title=EpiVario — Funding & Investors |url=https://www.vcbacked.co/company/epivario |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated